MAP2K7 and cancer: The safety of FAKi has already been tested in other cancer types (Mohanty et al., 2020), and they are now in clinical trials for UM as monotherapy and in combination with cobimetinib (NCT04109456) or with VS-6766 (NCT04720417, NCT03875820), a dual RAF/MEK inhibitor that received FDA breakthrough therapy designation for low-grade serous ovarian cancer (Ishii et al., 2013).